bioMerieux : H1 2024 results and guidance raised
>Q2: organic growth of +10% - Underlying operating margin : 16.1% - Q2 sales were € 937m (consensus: € 913m est.), with organic growth of +10%, i.e. € 1,902m at end-June (+7.4%% and +9.9% cc / consensus: € 1,878m est.) for H1 underlying operating profit of € 306m, i.e. 16.1% of sales (consensus: € 300m est.), impacted by a forex effect of -€ 44m.The installed base in molecular biology stood at 26,100 for FilmArray and 1,450 for SpotFire.The guidance has been...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.